# COLUMBA (NCT03277105)

> A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: subcutaneous daratumumab
- Indication: relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03277105
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Dara SC; Dara IV
- Enrollment: 522
- Primary outcome: Overall Response Rate (ORR)
- Primary outcome: Maximum Trough Concentration (Ctrough) of Daratumumab

## Some of the questions raised in the 30 most recent indexed sources

_Automated from the 30 newest of 31 indexed sources (May 2019 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether a fixed subcutaneous dose suits all body-weight groups compared with weight-based intravenous dosing
- Whether neutropenia and diarrhea differ between subcutaneous and intravenous daratumumab
- Whether subcutaneous daratumumab improves patient treatment satisfaction and quality of life compared with intravenous dosing

## Indexed commentary on COLUMBA so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 18 posts on X
- 8 podcast episodes
- 5 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=columba-nct03277105

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03277105", "email": "<work email>"}; the inbox owner confirms by the emailed link.
